Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 10Recurrence 4Neurofibrosarcoma 2Myeloproliferative Disorders 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Wilms Tumor 1Vascular Neoplasms 1Uterine Neoplasms 1Uterine Diseases 1Solitary Fibrous Tumors 1Smooth Muscle Tumor 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdoid Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Nerve Sheath Neoplasms 1Neoplasms, Adipose Tissue 1Neoplasms by Site 1Neoplasms 1Myoepithelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lymphoma 1Liposarcoma, Myxoid 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 8Magnetic Resonance Spectroscopy 7Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Nivolumab 4Etoposide 4Dexamethasone 4Biopsy 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Immunotherapy, Adoptive 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2etoposide phosphate 2cemiplimab 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × selinexor × 90 days × Clear all
NCT05322330 2026-06-02

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

The First Affiliated Hospital of Soochow University

Phase 2 Completed
20 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡